Ariadne

Ariadne (4C-D; BL-3912; dimoxamine), the alpha-ethyl homolog of the hallucinogenic amphetamine DOM, is a potent and selective agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors that is distinguished by a striking dissociation between receptor activation and hallucinogenic effect in humans. First synthesized by Alexander Shulgin in 1968 and advanced through Phase II clinical trials at Bristol-Myers Laboratories in the early 1970s under the development code BL-3912A (the pharmacologically preferred R-enantiomer), the compound produced rapid remission of psychotic symptoms in schizophrenia and bipolar patients at 50 to 100 mg per day, nearly complete reversal of motor deficits in Parkinson's disease patients at 100 mg per day, and improved cognitive alertness in geriatric subjects at 50 mg per day, all without hallucinogenic effects at doses up to and beyond 300 mg. Development was halted for strategic economic reasons rather than for safety or efficacy concerns, and the actual clinical data from the Bristol-Myers trials were never publicly disclosed.

The molecular pharmacology of Ariadne was formally characterized by the Cunningham, Sames, and McCorvy laboratories at Columbia University in a 2022 publication in ACS Chemical Neuroscience. The R-enantiomer binds the human 5-HT2A receptor with a Ki of 53 nM (radioligand displacement against [125I]-DOI), activates Gq-coupled signaling with an EC50 of 149 nM and an Emax of 83 percent relative to serotonin, and produces calcium flux with an EC50 of 30 nM and an Emax of 96 percent. The compound shows no substantial bias between Gq/11 and beta-arrestin2 signaling pathways. Instead, the non-hallucinogenic profile is attributed to a consistent 4- to 6-fold reduction in potency and a 10 to 20 percent reduction in maximal efficacy across all measured signaling channels relative to the hallucinogenic reference compound DOM. This "signaling efficacy hypothesis" proposes that the lower overall transduction amplitude, rather than pathway-selective biased agonism, accounts for the preservation of therapeutic effects in the absence of hallucination.

Selectivity profiling across a 44-target safety panel identified only the 5-HT2A and 5-HT2B receptors as targets displaced above 50 percent at 10 micromolar concentration. The compound has no measurable activity at dopamine, norepinephrine, or serotonin transporters (IC50 values exceeding 50 micromolar), no activity at dopamine D1 or D2 receptors, and weak submicromolar activity at 5-HT1A, 5-HT1D, 5-HT1E, and 5-HT1F receptors. In mice, subcutaneous administration at 10 mg/kg produces peak plasma concentrations of approximately 467 ng/mL at 15 minutes, a brain-to-plasma ratio of 10.23 at 1 hour, and a plasma elimination half-life of approximately 2.1 hours, confirming high central nervous system penetration.

Preclinical studies in auxilin-knockout mice (a genetic model of Parkinson's disease) demonstrated that a single 10 mg/kg dose of (R)-Ariadne restored balance beam performance to wildtype levels and eliminated hind limb clasping scores, mirroring the effects of levodopa despite the compound's lack of dopaminergic receptor or transporter activity. In the novelty-suppressed feeding test, a sustained anxiolytic-like effect was observed 7 days after a single administration, consistent with the neuroplasticity-dependent mechanisms proposed for 5-HT2A agonist therapeutic effects. A 2024 patent application by Columbia University (WO2024073601A2) claims therapeutic applications across movement disorders, neuropsychiatric conditions, cognitive impairment, substance use disorders, and catatonia. This monograph reviews the chemistry, stereochemistry, and synthesis of Ariadne; the receptor pharmacology and signaling mechanism in molecular detail; available pharmacokinetic data; the historical clinical evidence from Bristol-Myers and the contemporary preclinical pharmacology from the Sames laboratory; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a structured comparative assessment of five non-hallucinogenic 5-HT2A receptor agonists against Ariadne on five competency standards.